Working in the ChAdOx1 nCoV-19 trial team, I contribute to measuring the magnitude, longevity and phenotype of the T cell response to the SARS-CoV-2 vaccine. Lead for the variants trial, I am also collaborating with the Dong Group to explore in depth the vaccine response to challenge by emerging variants of concern.
Before The Jenner Institute, I worked with Professor John Todd at the Diabetes and Inflammation Laboratory (DIL) in the Wellcome Centre for Human Genetics. Here, I helped to develop a novel single cell sequencing technology which combines mRNA and protein quantitation. This new assay has now been used to explore regulatory T cell populations in autoimmune disease. I also performed flow cytometric phenotyping analyses for biomarker identification in clinical trial samples from patients with type 1 diabetes, with specialist training in the purification of specific lymphoid populations by flow cytometric sorting (BD FACSAria Fusion).
Prior to DIL, I worked for 2 years in Analytical Development at Immunocore, a Biotech with clinical stage T cell receptor therapies. My Doctoral training under Professor Margaret Callan at Imperial College London, studied the role of Natural Killer Cells in dysfunctional inflammation
Low-dose IL-2 reduces IL-21+ T cell numbers and induces anti-inflammatory gene expression in type 1 diabetes
Zhang J. et al, (2022), Nature Communications
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients
Zhang J-Y. et al, (2022)
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses
Ogbe A. et al, (2021)